Crossmark

Inhibition of ACAT as a Therapeutic Target for Alzheimer's Disease Is Independent of ApoE4 Lipidation

Crossref DOI link: https://doi.org/10.1007/s13311-023-01375-3

Published Print: 2023-07

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Valencia-Olvera, Ana C.

Balu, Deebika

Faulk, Naomi

Amiridis, Aspasia

Wang, Yueting

Pham, Christine

Avila-Munoz, Eva

York, Jason M.

Thatcher, Gregory R.J.

LaDu, Mary Jo https://orcid.org/0000-0003-2141-1450
Funding

Funding for this research was provided by:

National Institute on Aging (R01 AG058068, R01 AG057008)

AbbVie (Sponsored Research)

University of Illinois at Chicago (Institutional Funds)

Anonymous (Philanthropic funding)
License Information

Text and Data Mining valid from 2023-07-01

Text and Data Mining valid from 2023-07-01

Version of Record valid from 2023-05-08
More Information

This article is maintained by: Elsevier

Article Title: Inhibition of ACAT as a Therapeutic Target for Alzheimer's Disease Is Independent of ApoE4 Lipidation

Journal Title: Neurotherapeutics

CrossRef DOI link to publisher maintained version: https://doi.org/10.1007/s13311-023-01375-3

Content Type: article

Copyright: Copyright © 2023 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.